Acarix

Acarix FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Acarix (ACARIX.ST) as of Nov 12, 2026 is 102.18 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 97.07 % — a change of 5.27% (higher).

FCF Conversion

102.18 %

YoY

5.27%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Acarix is 2025 102.18 % . FCF Conversion Rate (FCF/EBITDA) of Acarix was 2024 97.07 % . It decreases by 5.27% higher compared to the previous year.

The Acarix FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
91.44 SEK
Jan 1, 2019
95.95 SEK
Jan 1, 2020
88.40 SEK
Jan 1, 2021
92.76 SEK
Jan 1, 2022
97.45 SEK
Jan 1, 2023
104.56 SEK
Jan 1, 2024
97.07 SEK
Jan 1, 2025
102.18 SEK
The Acarix FCF Conversion history
YEARFCF ConversionYoY
102.18 %+5.27%
97.07 %-7.17%
104.56 %+7.30%
97.45 %+5.06%
92.76 %+4.93%
88.40 %-7.86%
95.95 %+4.93%
91.44 %-37.44%
146.17 %+231.71%
44.07 %-63.96%
122.25 %+8.32%
112.87 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Acarix Stock analysis

What does Acarix do? Acarix AB generates revenue through the sale of its primary medical device, the CADScor System, which utilizes phonocardiography for coronary artery disease monitoring. The system is designed for use by physicians, nurses, and laboratory technicians in clinical settings, featuring a chest patch with a recording head positioned at the fourth left intercostal space and a sensor on the sternum. Patients undergo a two-minute heart sound recording guided by audio cues and display instructions, after which the CAD-score is calculated and displayed for diagnostic purposes. The company's business model relies on direct sales of the CADScor System to healthcare providers, including hospitals and diagnostic laboratories, where the device is used for non-invasive rule-out diagnosis of coronary artery disease. The system's unique phonocardiography technique and algorithm-based scoring provide a streamlined diagnostic process, reducing the need for more invasive procedures and appealing to medical professionals seeking efficient diagnostic tools. Acarix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Acarix stock

FCF Conversion Rate (FCF/EBITDA) of Acarix is 102.18 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Acarix changed from 97.07 % to 102.18 %, representing a 5.27% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Acarix since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Acarix with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Acarix

All Key Metrics — Acarix